Literature DB >> 12599203

Inflammatory mediators and reversible myocardial dysfunction.

Hong Kan1, Mitchell S Finkel.   

Abstract

A variety of seemingly unrelated clinical conditions manifest the same effects on the heart. These effects include: (1) reversible myocardial dysfunction, (2) beta-adrenergic desensitization, and (3) activation of inflammatory mediators. We provide evidence supporting a role for cytokines, mitogen activated protein kinases (MAP kinases), and nitric oxide (NO) as common mediators of reversible myocardial dysfunction and beta-adrenergic desensitization. Data from animal models and human studies support a pathogenic role for these inflammatory mediators in ischemic as well as non-ischemic myocardial dysfunction. It is suggested that compensatory cellular programs are activated to provide short-term protection from brief periods of ischemia and infection. Continuous activation of these compensatory pathways leads to cardiomyopathy and chronic (congestive) heart failure. Elucidating the signaling pathways involved has the potential to provide the opportunity to exploit the cardioprotective advantages of these agents without bearing the burden of excessive stimulation. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12599203     DOI: 10.1002/jcp.10213

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

1.  Infliximab attenuates early myocardial dysfunction after resuscitation in a swine cardiac arrest model.

Authors:  James T Niemann; Scott Youngquist; John P Rosborough; Atman P Shah; Quynh T Phan; Scott G Filler
Journal:  Crit Care Med       Date:  2010-04       Impact factor: 7.598

2.  p38 MAP kinase inhibitor reverses stress-induced myocardial dysfunction in vivo.

Authors:  Fangping Chen; Hong Kan; Gerry Hobbs; Mitchell S Finkel
Journal:  J Appl Physiol (1985)       Date:  2009-02-12

Review 3.  Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.

Authors:  Matthias Pauschinger; Kumaran Chandrasekharan; Heinz-Peter Schultheiss
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

4.  Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.

Authors:  Ioannis Skiadas; Angelos Pefanis; Apostolos Papalois; Aspasia Kyroudi; Helen Triantafyllidi; Thomas Tsaganos; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

Review 5.  Complement and sepsis-induced heart dysfunction.

Authors:  Fatemeh Fattahi; Peter A Ward
Journal:  Mol Immunol       Date:  2016-12-05       Impact factor: 4.407

6.  N-acetylcysteine reverses cardiac myocyte dysfunction in a rodent model of behavioral stress.

Authors:  Fangping Chen; Jessalyn M Hadfield; Chalak Berzingi; John M Hollander; Diane B Miller; Cody E Nichols; Mitchell S Finkel
Journal:  J Appl Physiol (1985)       Date:  2013-05-30

7.  Interleukin-1β induces a reversible cardiomyopathy in the mouse.

Authors:  Benjamin W Van Tassell; Ignacio M Seropian; Stefano Toldo; Eleonora Mezzaroma; Antonio Abbate
Journal:  Inflamm Res       Date:  2013-05-07       Impact factor: 4.575

8.  Relationships among HIV infection, metabolic risk factors, and left ventricular structure and function.

Authors:  William Todd Cade; Edgar Turner Overton; Kristin Mondy; Lisa de las Fuentes; Victor G Davila-Roman; Alan D Waggoner; Dominic N Reeds; Sherry Lassa-Claxton; Melissa J Krauss; Linda R Peterson; Kevin E Yarasheski
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-06       Impact factor: 2.205

Review 9.  Human malarial disease: a consequence of inflammatory cytokine release.

Authors:  Ian A Clark; Alison C Budd; Lisa M Alleva; William B Cowden
Journal:  Malar J       Date:  2006-10-10       Impact factor: 2.979

10.  Clinical predictors of outcome in patients with inflammatory dilated cardiomyopathy.

Authors:  Konstantinos Karatolios; Volker Holzendorf; George Hatzis; Dimitrios Tousoulis; Anette Richter; Bernhard Schieffer; Sabine Pankuweit
Journal:  PLoS One       Date:  2017-12-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.